Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,464.00
+13.00 (0.90%)
Jun 19, 2026, 10:19 AM GMT
Hikma Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 402 | 359 | 190 | 188 | 421 |
Depreciation & Amortization | 204 | 189 | 190 | 185 | 169 |
Other Amortization | 8 | 8 | 8 | 8 | 11 |
Loss (Gain) From Sale of Assets | 1 | 1 | - | -6 | 1 |
Asset Writedown & Restructuring Costs | 26 | -29 | 61 | 179 | -35 |
Loss (Gain) From Sale of Investments | -1 | -1 | -2 | 2 | - |
Loss (Gain) on Equity Investments | - | -1 | - | - | 1 |
Stock-Based Compensation | 23 | 27 | 25 | 22 | 29 |
Other Operating Activities | 24 | 146 | 56 | 83 | 69 |
Change in Accounts Receivable | -97 | -144 | -24 | 4 | -166 |
Change in Inventory | -86 | -112 | -115 | -102 | 38 |
Change in Accounts Payable | 38 | 78 | 88 | 16 | 14 |
Change in Other Net Operating Assets | -106 | 43 | 131 | -49 | 86 |
Operating Cash Flow | 436 | 564 | 608 | 530 | 638 |
Operating Cash Flow Growth | -22.70% | -7.24% | 14.72% | -16.93% | 37.50% |
Capital Expenditures | -197 | -165 | -169 | -138 | -145 |
Sale of Property, Plant & Equipment | - | 10 | 18 | 1 | - |
Cash Acquisitions | - | -150 | -98 | -373 | - |
Divestitures | - | - | - | -1 | - |
Sale (Purchase) of Intangibles | -120 | -70 | -35 | -78 | -84 |
Investment in Securities | -2 | -2 | -26 | -15 | 3 |
Other Investing Activities | -69 | -4 | -23 | -3 | -12 |
Investing Cash Flow | -388 | -381 | -333 | -607 | -238 |
Short-Term Debt Issued | 349 | 387 | 437 | 380 | 383 |
Long-Term Debt Issued | 2,402 | 684 | 778 | 1,401 | 10 |
Total Debt Issued | 2,751 | 1,071 | 1,215 | 1,781 | 393 |
Short-Term Debt Repaid | -357 | -411 | -467 | -363 | -431 |
Long-Term Debt Repaid | -2,104 | -557 | -851 | -971 | -76 |
Total Debt Repaid | -2,461 | -968 | -1,318 | -1,334 | -507 |
Net Debt Issued (Repaid) | 290 | 103 | -103 | 447 | -114 |
Repurchase of Common Stock | -36 | -38 | - | -300 | - |
Common Dividends Paid | -185 | -175 | -137 | -125 | -120 |
Other Financing Activities | -94 | -78 | -97 | -80 | -53 |
Financing Cash Flow | -25 | -188 | -337 | -58 | -287 |
Foreign Exchange Rate Adjustments | 6 | -12 | -3 | -21 | -10 |
Net Cash Flow | 29 | -17 | -65 | -156 | 103 |
Free Cash Flow | 239 | 399 | 439 | 392 | 493 |
Free Cash Flow Growth | -40.10% | -9.11% | 11.99% | -20.49% | 68.84% |
Free Cash Flow Margin | 7.14% | 12.76% | 15.27% | 15.57% | 19.31% |
Free Cash Flow Per Share | 1.07 | 1.78 | 1.97 | 1.74 | 2.12 |
Cash Interest Paid | 83 | 84 | 82 | 68 | 50 |
Cash Income Tax Paid | 124 | 125 | 129 | 55 | 129 |
Levered Free Cash Flow | -66.13 | 293.88 | 449 | 244.38 | 269.75 |
Unlevered Free Cash Flow | -13 | 340.75 | 494.63 | 281.25 | 296.63 |
Change in Working Capital | -251 | -135 | 80 | -131 | -28 |